Congress Asset Management Co. boosted its position in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 3.4% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 60,479 shares of the company’s stock after purchasing an additional 2,000 shares during the period. Congress Asset Management Co. owned about 0.22% of Medpace worth $37,750,000 as of its most recent filing with the SEC.
Other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. bought a new position in shares of Medpace during the 2nd quarter worth approximately $1,323,047,000. State Street Corp raised its stake in Medpace by 4.2% in the 2nd quarter. State Street Corp now owns 710,895 shares of the company’s stock valued at $376,483,000 after acquiring an additional 28,666 shares during the period. Wasatch Advisors LP raised its stake in Medpace by 19.4% in the 1st quarter. Wasatch Advisors LP now owns 773,931 shares of the company’s stock valued at $371,634,000 after acquiring an additional 125,625 shares during the period. Renaissance Technologies LLC lifted its holdings in Medpace by 8.3% during the 1st quarter. Renaissance Technologies LLC now owns 504,668 shares of the company’s stock valued at $242,337,000 after purchasing an additional 38,760 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in Medpace by 19.4% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 375,033 shares of the company’s stock valued at $210,637,000 after purchasing an additional 60,883 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.
Analysts Set New Price Targets
MEDP has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $535.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. UBS Group began coverage on shares of Medpace in a report on Wednesday, September 30th. They issued a “neutral” rating and a $673.00 price target on the stock. Jefferies Financial Group restated a “hold” rating on shares of Medpace in a research report on Monday, September 14th. Mizuho upped their target price on Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Finally, Barclays set a $600.00 price target on Medpace in a report on Thursday, July 23rd. Three investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, Medpace presently has an average rating of “Hold” and a consensus target price of $602.27.
Medpace Stock Down 2.8%
Shares of MEDP traded down $17.61 during mid-day trading on Tuesday, hitting $602.90. 219,122 shares of the company’s stock were exchanged, compared to its average volume of 330,176. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90. The stock’s 50-day simple moving average is $600.57 and its 200-day simple moving average is $522.82. The firm has a market cap of $16.83 billion, a price-to-earnings ratio of 35.34, a price-to-earnings-growth ratio of 2.67 and a beta of 1.18.
Medpace (NASDAQ:MEDP – Get Free Report) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. During the same quarter in the prior year, the business posted $3.10 earnings per share. The firm’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.
Insider Activity
In related news, CEO August Troendle sold 21,966 shares of the business’s stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $625.47, for a total value of $13,739,074.02. Following the completion of the transaction, the chief executive officer owned 338,225 shares of the company’s stock, valued at $211,549,590.75. The trade was a 6.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders sold 336,140 shares of company stock worth $208,008,328. Corporate insiders own 20.50% of the company’s stock.
Medpace Profile
Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.
Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.
Featured Articles
- Five stocks we like better than Medpace
- Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI
- Lamb Weston’s Turnaround Is Starting to Look Real
- These 3 Stocks Got the Most Love From Analysts in September
- Record French Debt Could Create Opportunities for U.S. Market Operators
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
